TRC Capital Corporation, famed for making discounted offers to buy shares well below the SEC’s 5% threshold, has approached Viatris shareholders. The newly-formed company, like many others, has urged shareholders to say no.
Viatris has urged shareholders to reject an unsolicited, below-market mini-tender offer from TRC Capital Corporation, the latest made by the infamous Canadian investor, whose tactics have received sharp criticism from companies and the US Securities and Exchange Commission alike.
TRC is attempting to purchase up to 6,000,000 Viatris shares – equivalent to a 0.497% stake – for $16.50 in...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
